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Abstract
As of 2004, it was estimated that 2.2 million Americans were
diagnosed with paroxysmal or persistent atrial fibrillation
(AF) resulting in one out of every six strokes in the United
States. AF leads to a reduction in pumping efficiency of the
heart increasing the risk of several serious sequelae such as
thromboembolic stroke and congestive heart failure (CHF). It
also results in a reduced quality of life for the patients suffering from the disease. Patients with AF require appropriate
antiarrhythmic therapy to control symptoms and prevent
adverse effects of the condition. Multaq® (dronedarone), an
antiarrhythmic drug approved for AF in patients in sinus
rhythm with a history of paroxysmal or persistent AF,
showed promise as an alternative to amiodarone therapy
after its approval in July 2009. However, recent reports have
shown that dronedarone use doubles mortality risk and serious adverse events in certain patient populations specifically
those with heart failure or permanent AF. This review evaluates the research that brought dronedarone to the market
and reassesses the appropriateness of its use based upon
recent findings.
Introduction
Atrial fibrillation (AF), a supraventricular tachyarrhythmia,
and associated atrial flutter are two of the most common
clinically significant cardiac arrhythmias. 1-4 In 2004, an estimated 2.2 million Americans had paroxysmal or persistent
AF, affecting roughly 0.4 percent of the general population,
with an increased prevalence of greater than 6 percent in
those over 80 years of age. Patients with non-rheumatic AF
are two to seven times more likely to suffer an ischemic
stroke than those without AF. Additionally, one in every six
strokes occurs in a patient with AF. According to the Framingham study, overall stroke risk in patients aged 80 to 89
drastically increases to 23.5 percent from 1.5 percent in patients aged SO to 59. While AF itself is not directly life threatening, it results in reduced pumping efficiency of the heart,
which increases the risk of several serious sequelae including
thromboembolic stroke and CHF. Quality of life measures in
AF patients are drastically reduced due to multiple symptoms associated with the condition including palpitations,
dyspnea, chest pain, fatigue and dizziness. However, these
symptoms vary between patients.
To manage patients with AF, it is paramount to address the
issues related to the arrhythmia itself and to strive for the
prevention of a thromboembolism.1,2,4 Management of dysrhythmias in patients with persistent AF can be done in two
ways: restoration and maintenance of sinus rhythm or permitting AF to continue and ensuring the ventricular rate is
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controlled. Relief of symptoms, prevention of embolism and
avoidance of cardiomyopathy are the main reasons for restoration and maintenance of sinus rhythm in patients with AF. Dysrhythmias can be managed pharmacologically or nonpharmacologically via electrical cardioversion, surgical or
catheter ablation, pacing or with an internal atrial cardioverter /defibrillator.
Pharmacologically, the antiarrhythmic drug class is broken
down into subcategories.s These include type I sodium channel blockers, which can be further divided into Ia, lb, le according to dissociation rates from the sodium channels; type
II beta adrenergic receptor antagonists; type III drugs that
prolong the refractory period by prolonging the action potential; and type IV non-dihydropyridine calcium channel
blockers. A specific drug or class should be chosen based on
the cause of the arrhythmia, pharmacokinetics and patientspecific conditions. For more information on antiarrhythmic
drug classes refer to Chapter 29: Anti-arrhythmic drugs in
the twelfth edition of"Goodman and Gilman's the Pharmacological Basis ofTherapeutics." 2
One of the newer antiarrhythmics to come onto the market,
dronedarone (Multaq®Sanofi U.S., Bridgewater, N.J.), was
approved by the Food and Drug Administration (FDA) in July
2009 to reduce the risk of hospitalization for AF in patients
in sinus rhythm with a history of paroxysmal or persistent
AF.6-9 This drug was formulated to mimic the effects of amiodarone, a class III antiarrhythmic agent approved for the
treatment of refractory life-threatening ventricular arrhythmias; however, dronedarone was intended to have an
improved safety and tolerability profile compared to amiodarone. The typical adult dosage of dronedarone is 400 mg by
mouth twice daily, administered as one tablet with the morning meal and one tablet with the evening meal. It should not
be used in patients with permanent AF, as this use is associated with an increased risk of death, stroke and heart failure.
Additionally, dronedarone carries a boxed warning contraindicating its use in patients with New York Heart Association
(NYHA) class IV heart failure, patients with symptomatic
heart failure with recent decompensation and in patients in
AF who cannot be cardioverted into normal sinus rhythm.
Recent reports have shown that dronedarone use doubles
mortality risk and serious adverse events in these patient
populations. The purpose of this review is to evaluate the
research that brought this drug to the market and to reassess
recent findings questioning the appropriateness of its use.
Clinical Trial Evaluations
The European Trial in Atrial Fibrillation or Flutter Patients
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Receiving Dronedarone for the Maintenance of Sinus Rhythm
(EURIDIS) and The American-Australian-African Trial with
Dronedarone in Atrial Fibrillation or Flutter Patients for the
Maintenance of Sinus Rhythm (ADONIS) trials were evaluated by the FDA for the approval of dronedarone in the
United States. Additional information gathered from the
ATHENA trial also supports the use of dronedarone in AF.
EURIDIS/ADONIS (2003) The results of two identical,

placebo-controlled, multicenter, double-blind, parallel group
trials were published in The New England journal of Medicine
in late 2007.10 The objective of these trials was to assess if
dronedarone was superior to placebo for maintaining sinus
rhythm after electrical, pharmacologic or spontaneous conversion from AF or atrial flutter. The two trials involved in
this study were EURIDIS and ADONIS. Inclusion and exclusion criteria were deemed appropriate for each study's purpose.
The participants were randomized into either the placebo
group or the dronedarone group. In order to meet 90 percent
power, for both EURIDIS and ADONIS, 368 patients in the
dronedarone group and 184 patients in the placebo group
had to complete the trial. 10 Neither trial met power due to
patients discontinuing treatment prior to completion of the
study. At one year, the rates of recurrence of AF were 64.1
percent in the dronedarone group and 75.2 percent in the
placebo group. The researchers concluded that dronedarone
reduced the incidence of a first recurrence and the incidence
of a symptomatic first recurrence within 12 months of the
trial start date. Some limitations of the trials include: the Jack
of comparison between dronedarone and other medications,
resulting in the inability to compare adverse events and efficacy; the inability to detect every episode of recurrent arrhythmia; the exclusion criteria was extensive and may not
be realistic in a normal practice setting; and patients who
received amiodarone previously could be enrolled in the trial
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immediately after discontinuing the drug.
ATHENA (2008) The results of the ATHENA study were published in The New England journal of Medicine in early

2009. 11 ATHENA assessed the effects of dronedarone on cardiovascular events in patients with AF or atrial flutter. The
trial was a randomized, double-blind, placebo-controlled
study conducted in 37 countries. Inclusion and exclusion criteria were deemed appropriate for the study's purpose.
The trial enrolled a total of 4,628 patients who were randomized to either the dronedarone group or the placebo group. n
Out of the 2,301 patients receiving dronedarone, 734 (31.9
percent) experienced a primary outcome event (i.e., hospitalization due to cardiovascular events or death). Of the
2,327 receiving placebo, 917 (39.4 percent) had a primary
outcome event. In order to meet a statistical power of 80 percent, the researchers estimated that 2,150 patients per group
were necessary. This trial did not meet power due to over 30
percent of the patients in the dronedarone group and the
placebo group discontinuing the trial prior to the conclusion
of the study. The results of ATHENA found the use of dronedarone significantly reduced the risk of hospitalization due
to cardiovascular events or death in these patients. Dronedarone was found to increase the time to first recurrence of
AF from 53 days with placebo to 116 days with the active
drug. Some limitations of the study including lack of comparison of dronedarone to other medications, the inability to
detect every episode of recurrent arrhythmia and the large
discontinuation rate of the dronedarone group (30.2 percent) may have limited the data regarding rates of adverse
events (Table 1).
While studies have shown support for dronedarone in AF
patients, several studies have brought its use into question,
specifically in patients with heart failure and permanent AF.

Table 1. Important data from the trials supporting dronedarone 10•11

Dronedarone dose

EURIDIS/ADONisto

ATHENA11

400 mg BID

400 mg BID

Time from randomization to first documented
recurrence of atrial fibrillation
for at least 10 minutes
Symptoms of atrial fibrillation,
the mean ventricular rate during
the first recurrence

Death from any cause, death from
cardiovascular causes, hospitalization due to
cardiovascular events

Number of patients randomized to dronedarone group

828

2301

Dronedarone patients who
completed the trial

680

1605

Dronedarone hazard ratio

0.75

0.76

Primary endpoint(s)

Secondary endpoints

Significant inclusion criteria
Significant exclusion criteria

;:: 21 years old, in sinus rhythm for at least 1 hour
before randomization
Permanent atrial fibrillation,
NYHA class III or IV heart failure,
use of other class I or III antiarrhythmics
July 2012 Volume 3, Issue 2

First hospitalization due to cardiovascular
events or death

2:

70 years old, previous stroke, left ventricular
ejection fractions 40%
Permanent atrial fibrillation, NYHA class IV
heart failure, planned major surgery, use of
other class I or II antiarrhythmics

THE PHARMACY AND WELLNESS REVIEW

59

Cardiology

Dronedarone: An Update to a Controversial Therapy for Atrial Fibrillation

ANDROMEDA (2003) The Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity
Decrease (ANDROMEDA) was a multicenter, double-blind,
placebo-controlled, randomized, parallel-group trial comparing dronedarone 400 mg twice daily with matching placebo.12 This trial was conducted at 72 hospitals throughout
several countries in Europe. The study aimed to enroll 1,000
patients to achieve a power of 90 percent with a two-sided
type 2 error of S percent. The study was designed to specifically evaluate dronedarone with heart failure by enrolling
patients classified as NYHA class III or IV heart failure. The
trial measured adherence to the study by conducting a pill
count at each study visit.
The primary endpoint was a composite of death from any
cause and hospitalization for worsening heart failure while
the secondary endpoints were death from all causes, hospitalization for cardiovascular causes or recurrence of AF. 12
Endpoints were considered to be cardiovascular unless an
unequivocal non-cardiovascular cause was established. The
study was initiated in June 2002, but terminated early by the
safety committee in early 2003 due to an increase in death
associated with the dronedarone group. At the time of termination, ANDROMEDA had enrolled 627 patients which was
not enough to meet power. A total of 37 patients died during
the study with 25 in the dronedarone group and 12 in placebo group (p=0.03). Very few patients reached 180 days of
follow-up causing a small percentage of patients to be included in statistical analysis. While the number of deaths due
to arrhythmia or sudden death was not different between the
two groups, more participants died due to worsening heart
failure with dronedarone compared to placebo (10 versus
two respectively). Dronedarone also had a higher rate of hospitalization for cardiovascular related cause compared to the
placebo arm (71 versus SO, p=0.02).
DIONYSOS (2008) A short-term, randomized, double-blind,
parallel-group study to evaluate the Efficacy and Safety of
Dronedarone versus Amiodarone in Patients with Persistent
Atrial Fibrillation (DIONYSOS) was published in 2010 to
compare the effectiveness of dronedarone to amiodarone in
patients with persistent AF.13 The study was conducted in
112 centers in 23 countries throughout the world between
2007 and 2008. The goal of this study was to compare the
benefit/risk ratio of dronedarone and amiodarone. The combined primary endpoint was defined as recurrence of AF or
premature study drug discontinuation for lack of efficacy and
intolerance.
Participants with documented AF for >72 hours for whom
cardioversion and antiarrhythmic treatment was deemed
necessary by study investigators were enrolled. A total of
4 72 patients were necessary to show a relative reduction in
primary endpoint of 30 percent in six months in dronedarone compared to amiodarone and a power of 80 percent with
a type I error of S percent (two-sided). The study achieved
power by enrolling 504 patients. Participants were randomized to dronedarone 400 mg twice daily or amiodarone 600
mg every day for 28 days, then 200 mg every day thereafter.
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The results showed amiodarone may be superior to dronedarone in the conversion of persistent AF patients. AF recurrence following cardioversion was lower in the amiodarone
group compared to the dronedarone group (24.3 percent vs.
36.S percent respectively, p<0.001). While it is known amiodarone has many complications, including an interaction
with warfarin and alteration of thyroid function, it may be
superior for conversion in these patients. A high percentage
of AF patients are taking warfarin for anticoagulation and
this may pose a problem; however, warfarin dosing can be
adjusted downward while taking amiodarone. It is also important to note the study used a lower dose of amiodarone
(600 mg/day for 28 days, then 200 mg/day thereafter) compared to previous studies. The SAFE-T study used much
higher dosing (800 mg/day PO for 14 days, then 600 mg/day
for 14 days, then 300 mg/day for the first year and 200 mg/
day thereafter) of amiodarone to show superiority to sotalol
than the investigators of DIONYSOS used when comparing to
dronedarone,7.14 This may cause over inflation of recurrence
rates of AF when using amiodarone in DIONYSOS, showing
amiodarone may be even more superior to dronedarone.
PALLAS (2011) The Permanent Atrial Fibrillation Outcome
Study Using Dronedarone on Top of Standard Therapy
(PALLAS) was a randomized, double-blind, placebocontrolled trial conducted in 489 centers throughout the
world.15 Patients enrolled had permanent AF documented
with electrocardiography 14 days before randomization and
six months earlier. The co-primary outcomes were composite
of stroke, myocardial infarction, systemic embolism or death
from cardiovascular cause and unplanned hospitalization for
cardiovascular cause or death. For a power of 90 percent,
10,800 participants were needed for the trial. The study began in July 2010 and was terminated in July 2011 for safety
reasons with a total of3,236 patients enrolled.
At the time of study termination, the first co-primary outcome occurred in 43 participants in the dronedarone group
compared to 19 in the placebo group (p=0.002). Participants
in the dronedarone group also experienced more secondary
outcomes, 127 versus 67 respectively (p<0.001). This significant increase in outcomes for the dronedarone arm caused
the safety board to terminate the study. The dronedarone
group also had a significantly higher rate of death including
death from cardiovascular causes, such as arrhythmia, and
higher rate of unplanned cardiovascular hospitalization compared to the placebo group.
PALLAS shows that dronedarone should not be used in patients with permanent AF due to a much higher incidence of
adverse effects. It may be more important to control rate and
prevent thrombosis in patients with permanent AF than to
administer an antiarrhythmic. The longer a patient is in AF,
the lower the chances of cardioversion with either pharmacological or non-pharmacological treatment.

Current Dronedarone Trials
The Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial
Fibrillation (AFRODITE) is currently underway to assess
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whether the addition of dronedarone to existing conventional rate control leads to a reduced ventricular rate after
one week of dronedarone treatment in patients with a high
heart rate at rest during AF.16 This is a phase IV study comparing the addition of dronedarone to a beta blocker, calcium
channel blocker or digoxin in an effort to reduce heart rate.
The study was completed in November 2011, but data is not
available at the time of this publication.
Several other studies evaluating the efficacy of dronedarone
are currently underway. Dronedarone pattern of use in patients scheduled for elective cardioversion (ELECTRA) is a
multi-center study in Canada evaluating patients with persistent AF who are undergoing elective cardioversion.17 The
objective of this study is to compare the rate of recurrence
with dronedarone to placebo within six months. Data have
not yet been released, even though the trial was expected to
be completed in 2011. The effects of dronedarone on AF burden in subjects with permanent pacemakers (HESTIA) is a
randomized, multicenter study to evaluate dronedarone's
effects on AF burden.ts HESTIA was terminated before study
completion, but at the time of this publication data from the
study have not been released.

Dronedarone and Heart Failure
Dronedarone has a black box warning for patients with
NYHA class IV heart failure or recent decompensation of
heart failure requiring hospitalization.7 This contraindication
was based on an increased risk of death noted in the ANDROMEDA study; however, the early termination of the study
does not allow for proper evaluation of dronedarone in heart
failure. It is important to note that in ANDROMEDA up to the
time of termination only 19 of 62 7 enrolled had class IV
heart failure.12 The majority of participants had class II
(252/627) and class III (356/627). Due to the early termination, it is not possible to discern which deaths from progressive heart failure were in class II, III or IV. Conversely, in the
ATHENA study, 21 percent of participants had CHF with
NYHA class II or III and 12 percent had LVEF <45 percent.11
The investigators of ATHENA claim a subgroup analysis indicates patients with CHF had a similar benefit to the entire
group, but due to a small population of heart failure patients,
this claim lacks substantial evidence.1 1 The published data of
ATHENA did not provide information on outcomes specifically for participants with heart failure. Based on information
from ANDROMEDA, even though dronedarone is only contraindicated for class IV heart failure, caution should be used
when administering dronedarone to patients with any class
of heart failure.12
Discussion
Dronedarone has been controversial since the ANDROMEDA
study, and its safety and efficacy profile ill AF therapy has not
been proven. When ANDROMEDA was prematurely terminated in 2003, the sponsor and authors continued analyses
on the data, searching for explanations of its findings. 12 The
study was not published until 2008, after other information
on dronedarone had been released and regulatory submissions were considered. Looking into the history of dronedarone, the initial new drug application (NDA) submitted in
July 2012 Volume 3, Issue 2
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2005 was not approved, citing poor results from ANDROMEDA as a reason.16 Sanofi-Aventis then reapplied in 2008,
using information from DIONYSOS and ATHENA in support
of dronedarone.17 While it was approved, the advisory committee recommended that patients with advanced (NYHA
class III or IV) heart failure be excluded from dronedarone
therapy and a black box warning be issued. However, the
package insert only lists a contraindication for class IV heart
failure.
This controversy places pharmacists in a pivotal role to ensure proper pharmacologic therapy for AF. Pharmacists are
crucial to drug utilization reviews and ensuring patients are
receiving the best pharmacological therapy. Drug utilization
reviews empower and help guide pharmacists' decisions in
appropriate therapy management in AF patients. Due to the
increased risk of death in heart failure patients, especially
those with permanent AF, pharmacists should be weary
when patients with heart failure have prescriptions for
dronedarone. International normalized ratio (INR) analyses
from DIONYSOS showed that dronedarone did not have as
significant an effect on INR levels compared to amiodarone,
indicating that dronedarone should be considered for patients on warfarin with AF.13 However, due to substantial
information on adjusting warfarin dosing with amiodarone,
pharmacists should not exclude using amiodarone with warfarin. Finally, it is important that pharmacists help to educate
physicians and other clinicians about the possible serious
consequences if dronedarone is not used properly.
AF results in an increased burden on quality of life, specifically in older patients. This population is often faced with a
poor prognosis in terms of venous thromboemboli and mortality secondary to worsening comorbidities such as heart
failure, coronary artery disease and hypertension. Control of
AF is typically achieved through rate or rhythm control and
anticoagulation. Dronedarone, a pharmacological agent used
for rate control, is currently indicated to reduce the risk of
hospitalization for AF in patients in sinus rhythm with a history of paroxysmal or persistent AF. However, due to findings from the trials studied, the safety and efficacy of dronedarone is in question. ANDROMEDA showed that dronedarone should not be used in patients with NYHA class IV heart
failure and may not be safe in patients with NYHA class II and
III heart failure. 12 PALLAS indicated dronedarone is not safe
in patients with permanent AF leading to its contraindication
in such patients.is DIONYSOS compared dronedarone to
amiodarone for use in patients with persistent AF, but
showed amiodarone may be superior to dronedarone in this
situation. 13 It is possible dronedarone may be used for patients with lone AF with no other complicating factors.

Conclusion
Dronedarone was approved in 2009 as an alternative to
amiodarone for the treatment of AF. However, the safety and
efficacy of dronedarone has still not been proven following
several recent studies. Additional studies in progress should
help to identify the place in practice for this agent. Pharmacists should take great caution when using dronedarone in
patients with NYHA class II, III and IV heart failure, as well as
patients with permanent AF.

THE PHARMACY AND WELLNESS REVIEW

61

Cardiology

Dronedarone: An Update to a Controversial Therapy for Atrial Fibrillation

References
1.
Sanoski CA, Bauman JL (2011). Chapter 25. The Arrhythmias. In ).T.
DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, L.M. Posey
(Eds), Pharmacotherapy: A Pathophysiologic Approach, Se. Retrieved
January 16, 2012 from www.accesspharmacy.com/content.aspx?a!D
=7972803.
2.
Brunton LL, Chabner BA, Knollmann BC (2011). Chapter 29. Antiarrhythmic drugs. Brunton LL, Blumenthal DK, Murri N, and HilalDandan R, Knollmann BC (Eds), Goodman and Gilman's the Pharmacological Basis of Therapeutics, 12e. Retrieved April 1, 2012 from www.
accesspharmacy.com.polar.onu.edu/content.aspx?ID=l6668583.
3.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults - national implications
for rhythm management and stroke prevention: the AnTicoagulation
and risk factors in atrial fibrillation (ATRIA) Study. ]AMA. 2001;285:
2370-5.
4.
Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et
al. ACC/AHA/ESC 2006 guidelines for management of patients with
atrial fibrillation - executive summary. Circulation. 2006;114:700-52 .
5.
Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al.
ACC/AHA/ESC guidelines for management of patients with atrial fibrillation: executive summary - a report of the American College of Cardiology/ American Heart Association task force on practice guidelines
and the European Society of Cardiology committee for practice guidelines and policy conferences (Committee to Develop Guidelines for the
Management of Patients with Atrial Fibrillation) Developed in collaboration with the American Society of Pacing and Electrophysiology.
Circulation 2001;104:2118-50.
6. Dronedarone [monograph on the Internet]. Tampa (FL): Gold Standard/Elsevier; 2012 [cited 2012 Feb 26]. Available from: www.clinical
pharmacology-ip.com/Forms/search.aspx?s=dronedarone.
7. Amiodarone [monograph on the Internet]. Tampa (FL) : Gold Standard/
Elsevier; 2012 (cited 2012 Feb 26]. Available from: www.clinical
pharmacology-i p.com/F or ms/ drugoptio ns.aspx?c pn um= 2 5&n=
Amiodarone.
8. Husten L. Experts disagree on when to use dronedarone (Multaq).
Cardiobrief[serial on the Internet] 2010. Accessed: February 26, 2012.
Available from: cardiobrief.org/2010/04/06/experts-disagree-onwhen-to-use-dronedarone-multaq/.
9. Carlson M. Rate vs rhythm control and suppression algorithms for the
management and prevention of atrial fibrillation. Medscape cardiology
[serial on the Internet] 2004;8(2). Accessed: February 26, 2012. Available from: www.medscape.org/viewarticle/487849.
10. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, TorpPedersen C, Connolly SJ. Effect of dronedarone on cardiovascular
events in atrial fibrillation. N Engl/ Med. 2009;360:668-77.
11. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kower PR, Capucci A, et al.
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or
flutter. N Engl/ Med. 2007;357:987-99.
12. Kober L, Torp-Pedersen C, McMurray JJV, Gotzsche 0, Levy S, Crijns H,
et al. Increased mortality after dronedarone therapy for severe heart
failure. N Engl] Med. 2008;358:2678-87.
13. Le Heuzey JV, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A
short-term, randomized, double-blind, parallel-group study to evaluate
the efficacy and safety of dronedarone versus amiodarone in patients
with persistent atrial fibrillation: the DIONYSOS study. ] Cardiovasc
Electr. 2010;21:597-605.
14. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial
fibrillation. N Engl] Med. 2005 May 5;352(18) :1861-72.
15. Connolly SJ. Camm AJ, Halperin JL, Joyner C, Alings M, Amerena). et al.
Dronedarone in high-risk permanent atrial fibrillation. N Engl/ Med.
2011;365:2268-76.
16. Clinical Trials (database on the Internet]. Bethesda (MD): National
Library of Medicine. 2012 [cited 2012 Mar 31]. Available from: clinicaltrials.gov/ct2/results?term=dronedarone.
17. Temple, Robert (Department of Health & Human Services, Food and
Drug Administration, Rockville, MD). Letter to: Nancy Barone Kribbs
(Drug Regulatory Affairs, Sanofi-Aventis U.S. Inc., Malvern, PA). 2006
Aug 29. 3 leaves. Located at: www.accessdata.fda.gov/drugsatfda_docs
/nda/2009/022425sOOOTOC.cfm.
18. Stockbridge, Norman (Division of Cardio-Renal Drug Products, Center
for Drug Evaluation and Research, Food and Drug Administration,
Rockville, MD). Divisional Memo to: Division of Cardio-Renal Drug
Products (Center for Drug Evaluation and Research, Food and Drug
Administration, Rockville, MD). 2009 Mar 27. 2 leaves. Available from:

62

THE PHARMACY AND WELLNESS REVIEW

www.accessdata.fda.gov/ drugsatfda_docs/nda/2009 /02 2425s000
TOC.cfm.

July 2012 Volume 3, Issue 2

